Benefits
Blood pressure reduction in hypertensive adults
Clinical trials in adults with mild hypertension show modest but consistent reductions in systolic and diastolic blood pressure with ABG10+® supplementation over weeks to months of use. Effect sizes smaller than first-line antihypertensives but useful as adjunct.
Cholesterol: no significant change in the cited trials
The cited trials do not show cholesterol lowering with this extract. In the hypercholesterolemic crossover trial (Valls 2022) the reported effect was a fall in diastolic blood pressure, not in total or LDL cholesterol. The 2026 lipoprotein trial found no statistically significant change in total cholesterol, LDL-C, HDL-C or triglycerides.
S-allyl cysteine bioavailability advantage
Aging fresh garlic converts unstable allicin into stable, water-soluble S-allyl cysteine (SAC). SAC is much more bioavailable than allicin and provides reproducible plasma levels — a key advantage over raw garlic or basic powders.
Platelet effects (not measured in the cited trials)
No cited trial of this extract measured platelet aggregation. A mild antiplatelet effect is proposed for garlic in general, but it has not been demonstrated for ABG10+ and is not a substitute for antiplatelet therapy.
Antioxidant capacity (laboratory measure)
Aged black garlic shows higher antioxidant capacity than raw garlic in laboratory assays, because aging concentrates polyphenols and Maillard reaction products. This is a laboratory measure, not a clinical antioxidant outcome.
Glycemic control: not measured for this extract
No randomized trial of this specific aged black garlic extract measuring blood glucose or HbA1c is cited. The three cited trials measured blood pressure and lipoprotein composition, not glycemic outcomes, so a glucose-lowering benefit cannot be claimed for this product.
Odorless and well-tolerated
Unlike raw garlic supplements, aged black garlic produces no garlic breath or odor and rarely causes GI upset. Practical advantage that supports long-term adherence for cardiovascular and metabolic applications.
Mechanism of action
ACE inhibition (angiotensin-converting enzyme)
ABG10+® decreases ACE activity — same mechanism as prescription ACE inhibitors (lisinopril, captopril, ramipril). Mechanism for blood pressure reduction even in patients on prescription antihypertensive therapy.
Nitric oxide production enhancement
Increases endothelial nitric oxide synthase activity — enhanced NO production providing vasodilation and antioxidant effects. Mechanism for BP improvement and broader cardiovascular benefits.
S-allyl-L-cysteine (SAC) bioactive accumulation
Aging process accumulates SAC — water-soluble organosulfur compound with cardiovascular, antimicrobial, immunomodulatory, hepatoprotective, antidiabetic, anti-obesity, neuroprotective, renal protective properties (per in vitro and in vivo evidence). Mechanism for multi-system benefits.
Melanoidins (Maillard reaction antioxidants)
Aging produces melanoidins — Maillard reaction products with antioxidant activity. Distinct from typical phenolic antioxidants. Mechanism contributing to overall antioxidant capacity demonstrated in clinical trials.
Antioxidant capacity enhancement
Combined SAC + polyphenols + flavonoids + melanoidins provide comprehensive antioxidant profile. Direct ROS scavenging + endogenous antioxidant enzyme system support. Mechanism for cardiovascular and metabolic benefits.
Xanthine oxidase modulation
ABG10+® reduces blood uric acid levels — mechanism likely involves xanthine oxidase modulation. Hyperuricemia is independent CV risk factor; reduction is added benefit.
Lipoprotein subclass remodeling
NMR studies show ABG10+® induces qualitative lipoprotein improvements: large HDL particles increase phospholipid + decrease triglyceride content; XXL-VLDL particles reduce cholesterol content. Mechanism beyond traditional 'lower LDL/raise HDL' framework — addresses lipoprotein quality relevant to atherogenic risk.
Clinical trials
Randomized triple-blind placebo-controlled trial (Serrano JCE, Castro-Boqué E, García-Carrasco A et al. 2023, Nutrients 15(17):3691, NCT04915053, doi:10.3390/nu15173691).
81 volunteers with Grade I hypertension already on prescribed antihypertensive drug treatment with persistent uncontrolled BP. Average 15-year hypertension history. Hospital Universitari Arnau de Vilanova (Lleida, Spain) and Atherothrombotic Disease Detection and Treatment Unit. 2-week placebo run-in phase + experimental phase. ABG10+® 250 mg/day vs placebo.
Additional 1.8 mmHg systolic + 1.5 mmHg diastolic BP reduction vs placebo in patients already ON prescription antihypertensive therapy — clinically meaningful adjunct evidence. Mechanism: enhanced NO release, increased antioxidant capacity, decreased ACE activity, lower blood uric acid. Foundational pivotal trial demonstrating real-world clinical utility as add-on therapy.
Randomized crossover double-blind sustained controlled trial (Valls RM, Companys J, Calderón-Pérez L et al. 2022, Nutrients 14(3):405, doi:10.3390/nu14030405).
67 hypercholesterolemic individuals with LDL-C ≥115 mg/dL. ABG10+® extract daily intake combined with dietary recommendations vs placebo. Crossover design.
In 67 hypercholesterolemic adults, the main reported result was a 5.85 mmHg diastolic blood pressure reduction versus placebo, mainly in men. The trial did not report a cholesterol reduction. Partly funded by the manufacturer (Pharmactive).
Randomized triple-blind placebo-controlled trial (Serrano JCE, Castro-Boqué E, García-Carrasco A et al. 2026, Front Nutr 13:1869617, doi:10.3389/fnut.2026.1869617, NCT04915053). This is a lipoprotein sub-analysis of the same cohort as the pivotal hypertension trial, not an independent study.
75 Grade I hypertensive participants. 250 mg ABG10+® or placebo daily for 12 weeks. NMR spectroscopy lipoprotein subclass and composition analysis. K-means and PLS-DA metabolic clustering.
Primary outcome was null: the extract produced no statistically significant change in total cholesterol, LDL-C, HDL-C or triglycerides. Only secondary exploratory NMR subclass analyses showed nominally significant differences (a fall in total and HDL particle number, and compositional shifts in large HDL and XXL-VLDL particles), which the authors describe as hypothesis-generating and requiring confirmation in adequately powered trials. Because this is a sub-analysis of the same NCT04915053 hypertension cohort, it is not independent evidence.